COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Profitability Analysis including gross margin, operating margin, net margin, return on assets, return on equity, return on invested capital. Compare profitability against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Profitability Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.

Return on Equity (ROE)

5.76%

Decreased from previous period

Positive ROE while 3088.T is negative. John Neff would see if this signals a clear edge over the competitor.

Return on Assets (ROA)

1.93%

Decreased from previous period

Positive ROA while 3088.T shows negative. Mohnish Pabrai might see this as a clear operational edge.

Return on Capital Employed (ROCE)

8.79%

Increased from previous period

ROCE 75-90% of 3088.T's 10.75%. Bill Ackman would need a credible plan to improve capital allocation.

Gross Profit Margin

19.37%

Decreased from previous period

Gross margin 50-75% of 3088.T's 27.30%. Martin Whitman would worry about a persistent competitive disadvantage.

Operating Profit Margin

4.91%

Increased from previous period

Operating margin below 50% of 3088.T's 12.27%. Michael Burry would investigate whether this signals deeper issues.

Net Profit Margin

2.46%

Decreased from previous period

Positive net margin while 3088.T is negative. John Neff might see a strong advantage vs. the competitor.

Select Chart Metric:

3349.T Profitability Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Return on Equity (ROE)

5.76%

Decreased from previous period

Positive ROE while 3088.T is negative. John Neff would see if this signals a clear edge over the competitor.

Return on Assets (ROA)

1.93%

Decreased from previous period

Positive ROA while 3088.T shows negative. Mohnish Pabrai might see this as a clear operational edge.

Return on Capital Employed (ROCE)

8.79%

Increased from previous period

ROCE 75-90% of 3088.T's 10.75%. Bill Ackman would need a credible plan to improve capital allocation.

Gross Profit Margin

19.37%

Decreased from previous period

Gross margin 50-75% of 3088.T's 27.30%. Martin Whitman would worry about a persistent competitive disadvantage.

Operating Profit Margin

4.91%

Increased from previous period

Operating margin below 50% of 3088.T's 12.27%. Michael Burry would investigate whether this signals deeper issues.

Net Profit Margin

2.46%

Decreased from previous period

Positive net margin while 3088.T is negative. John Neff might see a strong advantage vs. the competitor.

Select Chart Metric: